Comparison of blood tacrolimus concentrations in liver and kidney transplant recipients using ACMIA and MEIA immunoassays

Upsala Journal of Medical Sciences

Volumn 113, Issue 1, 2008, Pages 103-110

  Freire, Antonio ^a   Hermida, Jesús ^a   Tutor, J Carlos ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ARTICLE; BLOOD; COMPARATIVE STUDY; HUMAN; IMMUNOASSAY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METHODOLOGY; REPRODUCIBILITY;

HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 48949097830     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/2000-1967-220     Document Type: Article

References (20)

1. Chan YH, Ho CS, Shek CC, Wong KM, Chak WL, Choi KS, Chau KF, Li CS (2005) Measurement of whole blood tacrolimus level by high performance liquid chromatography tandem mass spectrometry in renal transplant recipients. Hong Kong J Nephrol ; 7: 65-69.
2. LeGatt DF, Shalapay CE CE, Cheng SB (2004) The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron Lx20 PRO analyser. Clin Biochem ; 37: 1022-30.
3. Napoli KL (2006) Is microparticle enzyme-linked immunoassay (MEIA) reliable for use for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant patiens. Ther Drug Monit; 28: 491-504.
4. Morand K, Huet E, Blanchet B, Astier A, Hulin A (2003) Evaluation of the heterogeneous immunoassay (ACMIA) for the measurement of blood cyclosporine on the Dehring dimension RXL clinical chemistry analyser. Ann Biol Clin; 61: 713-18.
5. Dessars B, Cotton F, Thiry P, Gulbis B (2003) Comparison of automated ACMIA and EMIT immunoassays for whole blood cyclosporin monitoring. Clin Lab; 49: 135-40.
6. Huet E, Morand B, Blanchet B, Astier A, Hulin A (2004) Evaluation of the new heterogeneous ACMIA immunoassay for the determination of whole blood cyclosporine concentrations in bone marrow, kidney, heart, and liver trasnplant recipients. Transpl Proc; 36: 1317-20.
7. Kagawa Y, Yonagawa M, Muraki Y, Iwamoto T, Mizutani H, Sugimura Y, Kojima M (2004) Comparison of cyclosporine concentrations in renal transplant recipients using ACMIA and mFPIA methods. Clin Biochem; 37: 1016-21.
8. Cattaneo D, Zenoni S, Murgia S, Merlini S, Baldelli S, Perico N, Gotti E, Ottomano C, Crippa A, Remuzzi G (2005) Comparison of different cyclosporine immunoassay to monitor C0 and C2 blood levels from kidney tansplant recipients: not simply overestimation. Clin Chim Acta; 355: 153-64.
9. Griffey MA, Hock KG, Kilgore DC, Wei TQ, Duh SH, Christenson R, Scott MG (2007) Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyser. Clin Chim Acta; 384: 48-51.
10. Hermida J, Fernández MC, Tutor JC (2005) Clinical significance of hematocrit interference in the tacrolimus II microparticle enzyme immunoassay: a tentative approach. Clin Lab; 51: 43-45.
11. Eksborg S (1981) Evaluation of method-comparison data. Clin Chem; 27: 1311-12.
12. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet; 16: 249-55.
13. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yaccobi A (2000) Bioanalytical methods validation- A revisit with a decade of progress. Pharm Res; 17: 1551-57.
14. Goffinet JS, Mullier F, Capron A, Cumps J, Wallemacq P (2007) Evaluation of three immunoassays to quantify tacrolimus: Impact of hematocrit (Abstract). Ther Drug Monit; 29: 508.
15. Bouzas L, Ortega FJ, Casado P, Arranz MI, Carcas A, Tutor JC (2007) Effect of the hematocrit and its correction on the relationship between blood tacrolimus concentrations obtained using the microparticle enzyme immunoassay (MEIA) and enzyme multiplied immunoassay technique (EMIT). Clin Lab; 53 (in press).
16. Kuzuya T, Ocura Y, Motegi Y, Moriyama N, Nabeshima T (2002) Interference of hematocrit in Tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit; 24: 507-11.
17. Tomita T, Homma M, Yuzawa K, Ohkohchi N, Hori T, Kaneko M, Hasegawa Y, Kojima Y, Nagasawa T, Kohda Y (2005) Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentration in therapeutic drug monitoring. Ther Drug Monit; 27: 94-97.
18. Oellerich M, Armstrong VW, Schütz E, Shaw LM (1998) Therapeutic drug monitoring of cyclosporine and tacrolimus. Clin Biochem; 31: 309-16.
19. Mano Y, Tsukada H, Kurihara T, Nomura M, Yokogawa K, Miyamoto K (2006) Development of dosage design of hepatic metabolizing drugs using serum albumin levels in chronic hepatic failure. Biol Pharm Bull; 29: 1692-99.
20. Cotton C, Johnston A, Holt DW (2007) A comparison of tacrolimus assays: HPLC/MS versus immunoassays (Abstract). Ther Drug Monit; 29: 508.